Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$56.25 USD
+1.10 (2.00%)
Updated Jul 25, 2024 11:12 AM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HALO 56.25 +1.10(2.00%)
Will HALO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
Other News for HALO
Halozyme to Report Second Quarter 2024 Financial and Operating Results
Healthcare 2024 Second Half Outlook
Laughing Water Capital Q2 2024 Letter
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
Halozyme price target raised by $10 at Benchmark, here's why